1. In Vivo
  2. >>Archive

Obesity Intervention: A New Era Of Discovery And Innovation

Device manufacturers are developing several next-generation devices for the minimally invasive treatment of obesity. Many of these emerging devices not only mimic the restriction and malabsorption mechanisms involved in bariatric surgery, but are also designed to influence the metabolic responses that are key to losing weight, improving outcomes, and impacting chronic disease.

If necessity is the mother of invention, then it should be no surprise that minimally invasive obesity devices continue to be a hot area for investment, research, and innovation. Obesity is one of the most compelling public health problems today, with nearly two-thirds of US adults and one-third of children either overweight or obese. By 2030, some 42% of all Americans are expected to be obese, up from 36% in 2010. Although the rate of growth in obesity has leveled off for some subpopulations since 2003, the numbers of morbidly obese (BMI [body mass index] > or = 40 kg/m2) continue to grow faster than any other group. Approximately 18 million Americans currently are considered morbidly obese, and experts predict the prevalence of morbid obesity will more than double in the years ahead, increasing from roughly 5% today to 11% over the next two decades. (See Exhibit 1.)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 
• By Eliza Slawther

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo